The US FDA conducted Good Manufacturing Practices (GMP) inspection of Shilpa Medicare Ltd’s Finished Dosage Formulation Facility (Sterile and Non-sterile) located at 5-20 to 5-26, Pharmaceutical Formulations SEZ, TSIIC, Jadcherla, Telangana State, India from 13-25, Feb 2020. At the conclusion of inspection, the Agency issued Form 483, with 15 observations. The company is preparing responses to the observations, which will be submitted to the Agency within 15 business days. The company is committed to address these observations promptly.
Shares of SHILPA MEDICARE LTD. was last trading in BSE at Rs.515.2 as compared to the previous close of Rs. 490.7. The total number of shares traded during the day was 46498 in over 888 trades.
The stock hit an intraday high of Rs. 515.2 and intraday low of 499.25. The net turnover during the day was Rs. 23903430.
